NeuroVia, Inc., an OHSU startup company, recently closed Series A equity financing, raising $11.45 million to support the company’s mission and commitment to developing therapeutics for the treatment of neurological disorders. Thomas Scanlan, Ph.D., professor of physiology and pharmacology and director of the OHSU program in chemical biology, is the founder of NeuroVia. Novartis Venture Fund, Sanofi-Genzyme Bioventures, and BioMed Realty Ventures participated in the Series A financing.
NeuroVia is committed to addressing unmet medical needs in neurological diseases. The company worked to develop a selective thyromimetic agent for the treatment of X-linked adrenoleukodystrophy (X-ALD), a genetic disease that primarily affects adolescent boys and young men with a spectrum of debilitating neurological symptoms and deficits. Thyromimetics are synthetic small molecule drugs that selectively activate thyroid hormone receptors and their signaling pathways in a subset of organs and tissues of the body. Scanlan is a leading expert in the design, synthesis, and biological actions of thyromimetic agents. NeuroVia’s drug development program is based on the hypothesis that activation of thyroid hormone signaling in cells that reside in or access the central nervous system will provide therapeutic benefit for X-ALD patients.
NeuroVia will use the Series A funding to support the initial stages of pre-clinical and clinical development for this program.